MMP2-Responsive Paclitaxel Prodrug and Its Nanopreparation Containing Cell Penetration Moiety for Cancer Targeting and Therapy
- Technology Benefits
- The prodrug formulation:ΓÇóIs much more safer to normal cells as compared to conventional systemsΓÇóEffectively allows for enhanced tumor targeting and sensitivityΓÇóEnables a higher drug loading efficiency as compared to conventional systemsΓÇóHas a lower risk of premature drug release/leakage as compared to prior art systemsΓÇóIs a novel amphiphilic polymer-drug conjugate containing a MMP2-cleavable peptideΓÇóHas a capability to self-assemble into micelles and forms mixed micelles with other polymersΓÇóIs associated with an enhanced drug internalization/permeability and retention effect as compared to conventional formulationsΓÇóWould be commercially useful for delivery for various anticancer agents for treatment of various cancer types such as ovarian cancer, breast cancer, non-small cell lung cancer, and head/neck cancer
- Detailed Technology Description
- None
- *Abstract
-
Paclitaxel is one of the commonly used antineoplastic agents. However, its use is highly limited due to presence of associated side effects such as neutropenia and neuropathy, as well as due to its low water solubility, off-target toxicity and acquired drug resistance. Various delivery systems have been used in the past. However, the existing systems are associated with many limitations such as low drug loading efficacy, premature drug release, and insufficient targetability. This approach discloses a novel, MMP2-responsive paclitaxel nanoprodrug formulation for an effective cancer targeting and therapy.
- *Principal Investigator
-
Name: Vladmir Torchilin
Department:
Name: Lin Zhu
Department:
- Country/Region
- USA
For more information, please click Here
